Macquarie Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Macquarie Group’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9	Closed	-$642	–	1911
2024 Q2	$642	Buy	+9	New	+$691	﹤0.01%	1865

Other funds holding VRCA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group's VRCA Position: Q3 2024 in Review

Macquarie Group sold out of Verrica Pharmaceuticals (VRCA) in Q3 2024, closing a stake of 9 shares — an estimated $642 sold.

Macquarie Group first reported a position in VRCA in Q2 2024 and held it in 1 quarter. The position peaked at $642 in Q2 2024. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

Macquarie Group reported no remaining Verrica Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 9 Verrica Pharmaceuticals shares in Q3 2024, an estimated $642.
Macquarie Group first reported a position in Verrica Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Macquarie Group's Verrica Pharmaceuticals position peaked at $642 in Q2 2024.
79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.